Biohaven Ltd., a New Haven-based bioscience firm, its chief executive officer and its chief financial officer are being sued ...

Shares of Biohaven Ltd. BHVN climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed the progress of the condition in a clinical trial.

--Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between ...

Biohaven acquired BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, as part of a February 2022 buyout of Channel Biosciences, a subsidiary of Knopp Biosciences.

Biohaven reported that its novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, demonstrated encouraging preliminary clinical activity ...

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 Provided by PR Newswire Mar 3, 2025 4:31am ...

Biohaven Pharmaceutical said on Monday its experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late ...

We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we dig into Biohaven’s plans and see Humira biosimilar ...

A Biohaven Pharmaceuticals drug developed to treat disease by modulating a neurotransmitter that’s important to normal brain function has failed a pivotal study in a rare neuromuscular disorder ...